The good news is that the team at UBS don’t believe that Vyvgart will have an overly large impact on CSL’s revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.
UBS - CSL no need to worry about Argenx
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$273.30 |
Change
-5.150(1.85%) |
Mkt cap ! $132.0B | |||
| Open | High | Low | Value | Volume |
| $275.10 | $275.24 | $272.37 | $199.1M | 726.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 200 | $273.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $273.34 | 12 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$273.21 |
Change
-5.150 ( 1.93 %) |
||||
| Open | High | Low | Volume | ||
| $275.24 | $275.24 | $272.38 | 30785 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CSL (ASX) Chart |